madman
Super Moderator
* Low endogenous testosterone is consistently associated with higher all- cause and cardiovascular mortality but most plausibly marks multimorbidity rather than causation.
* TRAVERSE established that physiologic transdermal testosterone replacement therapy was noninferior to placebo for 3- point major adverse cardiovascular events over ∼3 years, within a permissive margin and against a 61% discontinuation rate. Observational analyses linking normalization to lower mortality were not reproduced under randomization.
* Noninferiority over 3 years should not be read as long- term clinical equivalence.
* Atrial fibrillation, pulmonary embolism, acute kidney injury, fracture, and noncalcified plaque progression remain unresolved.
ABSTRACT
Whether low endogenous testosterone is causal for cardiovascular disease, and how the cardiovascular risk of testosterone replacement therapy should now be classified, remain contested, while US labeling has moved in 2 opposing directions within 16 months. We conducted a targeted narrative review reported in accordance with the Scale for the Assessment of Narrative Review Articles, searching MEDLINE and primary regulatory documents from January 2000 through July 2026. Evidence was graded with a prespecified 3- tier structured author- consensus rating separating established randomized findings, unresolved secondary signals, and evidentiary absence. Low endogenous testosterone is consistently associated with higher all- cause and cardiovascular mortality but most plausibly marks multimorbidity rather than causation. TRAVERSE established that physiologic transdermal testosterone replacement therapy was noninferior to placebo for 3- point major adverse cardiovascular events over ∼3 years, within a permissive margin and against a 61% discontinuation rate. Observational analyses linking normalization to lower mortality were not reproduced under randomization. Atrial fibrillation, pulmonary embolism, acute kidney injury, fracture, and noncalcified plaque progression remain unresolved. Blood pressure rises across the class; on ambulatory monitoring the magnitude differs by individual product rather than by route. Long- term exposure and nontransdermal formulations remain untested, and the age- related- hypogonadism limitation of use is now proposed for removal. Noninferiority over 3 years should not be read as long- term clinical equivalence. Safe use of testosterone replacement therapy requires appropriate patient selection, distinction between pathologic hypogonadism and functional or age- associated low testosterone, mapping of each recommendation to its evidentiary tier, and close multidisciplinary collaboration
Against that background, this review is organized around a single question: after TRAVERSE and the 2025 to 2026 US regulatory recalibration, how should the cardiovascular risk of testosterone replacement be classified, and how should the evolving label be read alongside the evidence base that informs it? Five subsidiary questions form the roadmap: whether low endogenous testosterone is a causal cardiovascular risk factor or a biomarker of multimorbidity; whether physiologic TRT alters the risk of atherosclerosis, arrhythmia, venous thromboembolism (VTE), or death; whether the adverse signals are early- window phenomena, chance findings, or mechanistically plausible harms; whether risks differ by formulation; and whether the short- to- medium- term noninferiority findings of TRAVERSE project into the long- term exposure typical of practice. Figure 1 summarizes the resulting synthesis and the boundaries of what the current evidence will support.
Conclusions
Three conclusions follow from the evidence synthesized in Figure 1.
First, low endogenous testosterone is a biomarker of multimorbidity and adverse metabolic state rather than a proven independent causal cardiovascular risk factor: strongly associated with mortality at low concentrations, weakly and inconsistently with nonfatal events, and related to AF in a manner better described as U- shaped than unidirectional.
Second, TRAVERSE demonstrated that physiologic, guideline- based transdermal testosterone therapy does not increase MACE over ∼3 years in men with confirmed hypogonadism and elevated cardiovascular risk, but the full cardiovascular profile is more nuanced than a single noninferiority conclusion. The large observational literature reporting that normalization of testosterone was associated with lower mortality and fewer cardiovascular events has not been reproduced in randomized form; equally, a 3- year noninferiority trial with substantial non-adherence is not the design that would detect long- term protection. The fair statement is that the randomized evidence accrued to date has not demonstrated a robust cardiovascular protective effect, and that long- term follow- up of both cohorts is required before either position is settled. Secondary signals from TRAVERSE (AF, PE, acute kidney injury, fracture), mechanistic considerations (erythrocytosis, atrial substrate effects, BP elevation), imaging evidence of plaque progression, and long- term real- world data mark the areas of persistent uncertainty, which are most consequential for prolonged therapy and for formulations other than transdermal gel.
Third, the regulatory recalibration (Figure 4) reflects this tension, acknowledging medium- term MACE non-inferiority while strengthening class- wide BP labeling and proposing to extend licensed use to a group in which outcome data remain limited. Physiologic transdermal TRT is therefore best regarded as a therapy with reassuring short- to- medium- term MACE data and incomplete long- term and formulation- generalizable safety evidence, and specifically not as a cardioprotective or uniformly cardiovascular- neutral intervention. Labeling and evidence necessarily advance on different timescales, and clinical decisions should remain anchored to the evidence.
Safe administration of TRT needs meticulous patient selection, precise differentiation between pathologic hypogonadism and functional or age- associated low testosterone, alignment of each recommendation with its level of evidence, and coordinated multi-disciplinary care across primary care, endocrinology, urology, hematology, and cardiology.
* TRAVERSE established that physiologic transdermal testosterone replacement therapy was noninferior to placebo for 3- point major adverse cardiovascular events over ∼3 years, within a permissive margin and against a 61% discontinuation rate. Observational analyses linking normalization to lower mortality were not reproduced under randomization.
* Noninferiority over 3 years should not be read as long- term clinical equivalence.
* Atrial fibrillation, pulmonary embolism, acute kidney injury, fracture, and noncalcified plaque progression remain unresolved.
ABSTRACT
Whether low endogenous testosterone is causal for cardiovascular disease, and how the cardiovascular risk of testosterone replacement therapy should now be classified, remain contested, while US labeling has moved in 2 opposing directions within 16 months. We conducted a targeted narrative review reported in accordance with the Scale for the Assessment of Narrative Review Articles, searching MEDLINE and primary regulatory documents from January 2000 through July 2026. Evidence was graded with a prespecified 3- tier structured author- consensus rating separating established randomized findings, unresolved secondary signals, and evidentiary absence. Low endogenous testosterone is consistently associated with higher all- cause and cardiovascular mortality but most plausibly marks multimorbidity rather than causation. TRAVERSE established that physiologic transdermal testosterone replacement therapy was noninferior to placebo for 3- point major adverse cardiovascular events over ∼3 years, within a permissive margin and against a 61% discontinuation rate. Observational analyses linking normalization to lower mortality were not reproduced under randomization. Atrial fibrillation, pulmonary embolism, acute kidney injury, fracture, and noncalcified plaque progression remain unresolved. Blood pressure rises across the class; on ambulatory monitoring the magnitude differs by individual product rather than by route. Long- term exposure and nontransdermal formulations remain untested, and the age- related- hypogonadism limitation of use is now proposed for removal. Noninferiority over 3 years should not be read as long- term clinical equivalence. Safe use of testosterone replacement therapy requires appropriate patient selection, distinction between pathologic hypogonadism and functional or age- associated low testosterone, mapping of each recommendation to its evidentiary tier, and close multidisciplinary collaboration
Against that background, this review is organized around a single question: after TRAVERSE and the 2025 to 2026 US regulatory recalibration, how should the cardiovascular risk of testosterone replacement be classified, and how should the evolving label be read alongside the evidence base that informs it? Five subsidiary questions form the roadmap: whether low endogenous testosterone is a causal cardiovascular risk factor or a biomarker of multimorbidity; whether physiologic TRT alters the risk of atherosclerosis, arrhythmia, venous thromboembolism (VTE), or death; whether the adverse signals are early- window phenomena, chance findings, or mechanistically plausible harms; whether risks differ by formulation; and whether the short- to- medium- term noninferiority findings of TRAVERSE project into the long- term exposure typical of practice. Figure 1 summarizes the resulting synthesis and the boundaries of what the current evidence will support.
Conclusions
Three conclusions follow from the evidence synthesized in Figure 1.
First, low endogenous testosterone is a biomarker of multimorbidity and adverse metabolic state rather than a proven independent causal cardiovascular risk factor: strongly associated with mortality at low concentrations, weakly and inconsistently with nonfatal events, and related to AF in a manner better described as U- shaped than unidirectional.
Second, TRAVERSE demonstrated that physiologic, guideline- based transdermal testosterone therapy does not increase MACE over ∼3 years in men with confirmed hypogonadism and elevated cardiovascular risk, but the full cardiovascular profile is more nuanced than a single noninferiority conclusion. The large observational literature reporting that normalization of testosterone was associated with lower mortality and fewer cardiovascular events has not been reproduced in randomized form; equally, a 3- year noninferiority trial with substantial non-adherence is not the design that would detect long- term protection. The fair statement is that the randomized evidence accrued to date has not demonstrated a robust cardiovascular protective effect, and that long- term follow- up of both cohorts is required before either position is settled. Secondary signals from TRAVERSE (AF, PE, acute kidney injury, fracture), mechanistic considerations (erythrocytosis, atrial substrate effects, BP elevation), imaging evidence of plaque progression, and long- term real- world data mark the areas of persistent uncertainty, which are most consequential for prolonged therapy and for formulations other than transdermal gel.
Third, the regulatory recalibration (Figure 4) reflects this tension, acknowledging medium- term MACE non-inferiority while strengthening class- wide BP labeling and proposing to extend licensed use to a group in which outcome data remain limited. Physiologic transdermal TRT is therefore best regarded as a therapy with reassuring short- to- medium- term MACE data and incomplete long- term and formulation- generalizable safety evidence, and specifically not as a cardioprotective or uniformly cardiovascular- neutral intervention. Labeling and evidence necessarily advance on different timescales, and clinical decisions should remain anchored to the evidence.
Safe administration of TRT needs meticulous patient selection, precise differentiation between pathologic hypogonadism and functional or age- associated low testosterone, alignment of each recommendation with its level of evidence, and coordinated multi-disciplinary care across primary care, endocrinology, urology, hematology, and cardiology.
